Apatinib, a class 1 heavy drug of Hengrui medicine, has held an expert review meeting last week

Apatinib, a heavyweight new drug of Hengrui pharmaceutical, held an expert review meeting last week According to people familiar with the matter, the result of the expert review meeting is approved production Expert review meeting is the core link of new drug approval After the expert review meeting, there are also on-site inspection, three in one comprehensive review and other links Apatinib is a kind of molecular targeted anti-tumor drug independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd., which is a me better drug modified on the basis of vandetanib and PTK787, and a small molecule vascular endothelial growth factor tyrosine kinase inhibitor with independent intellectual property rights Apatinib can be used in the treatment of advanced non squamous non-small cell lung cancer, gastric cancer, liver cancer, breast cancer It is suitable for cancer patients after the failure of other treatment methods Preclinical research shows that its antitumor effect is better than PTK787 According to the information on CFDA website, apatinib is a major special drug At present, no domestic enterprise has the production approval document of apatinib, and only Hengrui pharmaceutical is applying for production Apatinib is a molecular targeted anti-tumor drug It is a new drug independently developed by Jiangsu Hengrui Pharmaceutical Co., Ltd and a small molecule vascular endothelial growth factor tyrosine kinase inhibitor with independent intellectual property rights Apatinib can be used in the treatment of advanced non - squamous non - small cell lung cancer, gastric cancer, liver cancer, breast cancer It is worth mentioning that the indication of apatinib for production is gastric cancer, and the indication of liver cancer is undergoing clinical trials at the same time Guangfa Securities research report pointed out that the annual incidence of gastric cancer in China is more than 500000, and the annual incidence of liver cancer is more than 400000 At present, the monthly average cost of TiNi patients is more than 10000 yuan, and the market space for gastric cancer and liver cancer indications is expected to reach 1 billion yuan.